JUNSHI BIO - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

or completeness of this announcement, and expressly expressly disclaims any liability arising out of or in reliance upon the whole or any part of the contents of this announcement. assumes no responsibility for any losses caused by relying on such content.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

Shanghai Junshi Biomedical Technology Co., Ltd. (a joint stock limited company incorporated in the People's Republic of China) (Stock code: 1877)

Overseas regulatory announcement

This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

This is to set forth the "Shanghai Junshi Biomedical Technology Co., Ltd.’s Announcement on Signing a License Agreement with Fosun IMC” is for

See.

By order of the board of directors Shanghai Junshi Biomedical Technology Co., Ltd. Mr. Xiong Jun

Chairman

China, Shanghai, July 1, 2026

As of the date of this announcement, the Company’s Board of Directors includes Executive Directors Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun,

Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Wang Gang and Dr. Li Xin; non-executive directors Dr. Yao Sheng and Tang Yixian students; and independent non-executive directors Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun, Dr. Yang Jin and Chen Liang Sir.

*For identification purposes only

Securities code: 688180 Securities abbreviation: Junshi Biotechnology Announcement number: Lin 2026-038

Shanghai Haijunjunshi Biomedical Pharmaceutical Technology Co., Ltd.

Announcement on the signing of a licensing agreement with Fuxingxing Wanwanbangbang

The board of directors and all directors of the company guarantee that the contents of this announcement do not contain any false records or misleading statements. or major omissions, and shall bear legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

Important content reminder:

 On June 30, 2026, Shanghai Junshi Biomedical Technology Co., Ltd. (hereinafter referred to as "the company") Company") and Shanghai Fosun Pharma (Group) Co., Ltd. (hereinafter referred to as "Fosun Pharma"), a wholly-owned

Subsidiary Fosun IMC (Jiangsu) Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Fosun IMC") signed the "Award Grant"

License Agreement" (hereinafter referred to as the "License Agreement" or "Agreement"). According to the licensing agreement,

The company authorizes Fosun IMC to develop biopharmaceuticals regarding rocobizumab (JS005, anti-IL-17A monoclonal antibody) (hereinafter referred to as "Joint

products") in Greater China (including Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan region) development, registration, production and commercialization rights. Under the agreement, the company will receive RMB

215 million yuan (including tax) non-deductible and non-refundable down payment and is eligible for up to RMB

Development and sales milestone payments of RMB 1.125 billion (tax included), and double-digit net sales in Greater China

Percent tiered sales commission.

 The licensing agreement shall take effect on the date signed by both parties, unless it is terminated in advance according to the agreement. shall continue to be effective until the date when Fosun IMC completes all payment obligations under the agreement.

 This transaction does not constitute a related transaction, nor does it constitute the "Administrative Measures for Major Asset Reorganization of Listed Companies"

stipulated major asset reorganization.

 There are no major legal obstacles to the implementation of this transaction.

 The milestone payments and sales commissions agreed in the licensing agreement need to meet certain conditions. The production and sales of drugs from R&D to marketing approval are also susceptible to uncertainties.

ring. Investors are kindly requested to make prudent decisions and pay attention to preventing investment risks.

11. Overview of Transactions

On June 30, 2026, the company signed a licensing agreement with Fosun IMC. According to the licensing agreement

According to the proposal, the company authorized Fosun IMC to sell rocobizumab (JS005, anti-IL-17A monoclonal antibody) in Greater China. development, investment and investment in regions (including mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan Region)

registration, production and commercialization rights. According to the agreement, the company will receive RMB 215 million (including tax).

deductible and non-refundable down payment, and are eligible for a development loan of up to RMB 1.125 billion (tax included)

Development and sales milestone payments, as well as double-digit percentage tiered sales commissions on net sales in Greater China.

This transaction does not constitute a related transaction, nor does it constitute a transaction required by the "Measures for the Administration of Major Asset Restructuring of Listed Companies" major asset reorganization.

According to the "Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Rules" and "Shanghai Junshi Biomedical Technology

According to the Articles of Association of a Joint Stock Company, this transaction does not need to be submitted to the company’s board of directors and shareholders’ meeting for review.

22. Basic information of the counterparty of the agreement

Fosun IMC is a wholly-owned subsidiary of Fosun Pharma. Founded in 1994, Fosun Pharma is an innovative

A driven global pharmaceutical and health industry group. Fosun Pharma has formed an open, global innovative R&D system Department, focusing on unmet clinical needs, in-depth layout of core treatments such as tumors, immune inflammation, and neurodegenerative diseases

In the field of medical treatment, we will actively expand into areas such as chronic diseases and rare diseases, and create a long-term competitive product pipeline and comprehensive

solution. As of December 31, 2025, the total assets of Fosun Pharma (on a consolidated basis) were RMB

120.054 billion yuan, and the net assets attributable to shareholders of the listed company were RMB 48.742 billion. In 2025, the actual

The current operating income is RMB 41.662 billion, and the net profit attributable to shareholders of the listed company has reached RMB 3.371 billion. Yuan.

Fosun IMC has no related relationship with the company. In addition to this transaction, there is no relationship between Fosun IMC and the company.

There are other relationships in terms of property rights, business, assets, creditor's rights and debts, personnel, etc.

33. Basic information on the subject matter of the agreement

Nocobizumab is a specific anti-IL-17A monoclonal antibody independently developed by the company. IL (white blood cells Interleukin-17A is a pleiotropic cytokine whose dysregulation is associated with autoimmune diseases such as silver

It is closely related to the occurrence and development of diseases such as scabies, rheumatoid arthritis, and ankylosing spondylitis. rocoxibizumab

By binding with high affinity and selectivity to IL-17A homodimers and IL-17A/IL-17F heterodimers

It effectively blocks the binding of IL-17A to its receptor IL-17RA/IL-17RC, thus blocking the stimulation of downstream signaling pathways.

The release of active and inflammatory factors can effectively alleviate the symptoms of autoimmune diseases. Bacumab is now available Completed Chinese registration phase III clinical study in adult patients with moderate to severe plaque psoriasis and showed excellent results

Different efficacy and safety. In the 150 mg dose group, the PASI 90 response rate was 91% at week 16;

The PASI100 response rate reached 65% at week 52. In December 2025, rocoxibumab will be approved for the treatment of appropriate

NDA for adult patients with moderate to severe plaque psoriasis in combination with systemic therapy or phototherapy

(NDA) was accepted by the National Medical Products Administration. As of the disclosure date of this announcement, rocoxibumab is used for

All participants in the Phase II trial for the treatment of active ankylosing spondylitis (AS) have completed study follow-up. 44. Main contents of the agreement

(1) Licensed content

According to the agreement, the company authorizes Fosun Wanbang to: (1) engage in a cooperative product in the Greater China region

An exclusive license to develop, register and commercialize; (2) a company engaged in cooperative products in Greater China

Co-exclusive license to produce. (2) Financial terms

1. Down payment

After the agreement takes effect, Fosun IMC will pay the company RMB 215 million (tax included), which is non-deductible and non-deductible.

Refundable down payment.

2. Milestone payment According to the agreement, Fosun Wanbang will pay the company up to

Development and sales milestone payments of RMB 1.125 billion (tax included), including product development milestone payments

The maximum amount is RMB 180 million (including tax), and the sales milestone payment is up to RMB 945 million (including

tax).

3. Sales commission Based on the sales of the cooperative products in the Greater China region, Fosun IMC will pay the company for the sales of the cooperative products.

Double-digit percentage tiered sales commission on net sales in Greater China.

(3) Term and termination

The licensing agreement comes into effect on the date it is signed by both parties. Unless terminated early in accordance with the agreement,

This license agreement shall remain in effect until Fosun IMC has fulfilled all payment obligations under this agreement. until date. All payment obligations under this agreement include the down payment, development mileage and

Monument payments, sales milestone payments and sales commissions. Among them, the sales commission period is for each company in the cooperation area.

region, starting from the date of first commercial sale of the cooperative product in that region, whichever is later in the following (1)-(3)

The period ends on: (1) The fifteenth anniversary of the first commercial sale of the cooperative product in the region; or

(2) The date when all valid claims for the core molecular patent rights agreed in the agreement expire; or (3) Cooperation

All regulatory exclusivity periods (such as data protection periods) for the product in that territory expire.

(4) Applicable law and dispute resolution

If a dispute arises between the two parties that cannot be resolved through negotiation, it shall be submitted to the Shanghai Arbitration Commission for arbitration according to the application

Arbitration shall be conducted under the arbitration rules in effect at the time. The place of arbitration shall be Shanghai, China. 55. The impact of the agreement on the company

Fosun IMC has established a strong commercialization team and mature commercialization experience in the field of autoimmune diseases.

system, the signing of this licensing agreement will accelerate the subsequent development of rocobizumab in Greater China.

Registration and commercialization process, leveraging Fosun IMC’s development and market advantages in the field of autoimmune diseases, this time

The cooperation will further broaden the company's strategic layout in this field and provide new products for the unmet clinical needs of the market. treatment options and will have a positive impact on the company's ongoing operations. The signing of this agreement will not affect the company's

Business independence and no harm to the interests of the company and shareholders.

Sixty-six, risk warnings

Pharmaceutical products are characterized by high technology, high risk, and high added value. From research and development to obtaining marketing approval,

The production and sales of accurate products are easily affected by some uncertain factors. In addition, the terms stipulated in the agreement Chengbei payment and sales commission need to meet certain conditions, the final payment amount and the impact on the company's future operating income

The impact on profits is uncertain. Investors are kindly requested to make prudent decisions and pay attention to preventing investment risks.

The company will strictly comply with relevant regulations and perform its information disclosure obligations on the subsequent progress of the project in a timely manner. related to

The company's information is disclosed in the company's designated media "China Securities Journal", "Shanghai Securities News", "Securities Times" and

The announcement published on the Shanghai Stock Exchange website shall prevail.

Announcement is hereby made.

Shanghai Junshi Biomedical Technology Co., Ltd.

board of directors July 2, 2026